Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma.
Trending
- NPC urges e-birth registration in Sokoto
- NOH Jos records 154 major surgeries, ₦72m revenue
- AWARD fellows call for women’s inclusion in agri policies
- NEMA trains stakeholders on flood preparedness, camp management
- NSPHCDA hands over rehabilitated Yidna PHC, charges community on ownership
- [VIEWPOINT] Extreme weather demands a new standard of preparedness, by Kobus van Zyl
- [VIEWPOINT] Africa’s green transition must not become a new colonial project, by Dr Melania Chiponda
- Naira strengthens to N1,400/$ in parallel market as official rate hits N1,365
